https://doi.org/10.4081/gc.2025.13157
0
0
0
0
Smart Citations0
0
0
0
Citing PublicationsSupportingMentioningContrasting
See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Hepatocellular carcinoma management in older adults and its relation with frailty
Frailty, defined as a condition of extreme clinical vulnerability, is a crucial predictor of survival in elderly cancer patients. Frailty is not a specific disease but rather a combination of physical, cognitive, and social factors that compromise the patient’s ability to effectively respond to stressful situations. The majority of patients diagnosed with hepatocellular carcinoma (HCC) are over 65 years old, making it essential to also assess comorbidities and conditions that may predispose to frailty, as these can influence prognosis. Therefore, identifying a clinical tool to standardize the concept of the “frail elderly patient” is essential to ensure an appropriate medical approach for this population. In this review, we examine various frailty assessment tools and evaluate their application in different therapeutic and management settings for elderly patients with HCC. Understanding the impact of frailty in elderly patients with HCC can help optimize clinical management, thereby reducing resource waste for the healthcare system and minimizing stress factors for the patient.
Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol 2018;43:13-25.
DOI: https://doi.org/10.1007/s00261-017-1209-1
Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-43.
DOI: https://doi.org/10.7150/jca.7279
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
DOI: https://doi.org/10.1053/j.gastro.2007.04.061
Cabibbo G, Aghemo A, Lai Q, et al. Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Dig Liver Dis 2022;54:452-60.
DOI: https://doi.org/10.1016/j.dld.2022.01.122
AIOM. Gestione multidisciplinare del paziente con epatocarcinoma. 2023. Available from: https://www.aiom.it/linee-guida-aiom-2023-gestione-multidisciplinare-del-paziente-con-epatocarcinoma/.
Byrd K, Alqahtani S, Yopp AC, Singal AG. Role of multidisciplinary care in the management of hepatocellular carcinoma. Semin Liver Dis 2021;41:1-8.
DOI: https://doi.org/10.1055/s-0040-1719178
Cho E, Cho HA, Jun CH, et al. A review of hepatocellular carcinoma in elderly patients focused on management and outcomes. In Vivo 2019;33:1411-20.
DOI: https://doi.org/10.21873/invivo.11618
Kumar V, Abbas AK, Aster JC. Robbins and cotran pathologic basis of disease. Amsterdam, The Netherlands: Elsevier Health Sciences; 2014.
Oishi K, Itamoto T, Kohashi T, et al. Safety of hepatectomy for elderly patients with hepatocellular carcinoma. World J Gastroenterol 2014;20:15028-36.
DOI: https://doi.org/10.3748/wjg.v20.i41.15028
Kinoshita A, Koike K, Nishino H. Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. Geriatr Gerontol Int 2017;17:189-201.
DOI: https://doi.org/10.1111/ggi.12747
Karanam G, Arumugam MK. Potential anticancer effects of cyclo(-Pro-Tyr) against N-diethyl nitrosamine induced hepatocellular carcinoma in mouse through PI3K/AKT signaling. Environ Toxicol 2022;37:256-69.
DOI: https://doi.org/10.1002/tox.23395
Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014;60:110-7.
DOI: https://doi.org/10.1016/j.jhep.2013.08.011
Kanwal F, Kramer JR, Duan Z, et al. Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans. Clin Gastroenterol Hepatol 2016;14:301-8 e1-2.
DOI: https://doi.org/10.1016/j.cgh.2015.08.010
Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723-30.
DOI: https://doi.org/10.1002/hep.28123
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
DOI: https://doi.org/10.1016/j.jhep.2011.12.001
Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
DOI: https://doi.org/10.1002/hep.24199
Verslype C, Rosmorduc O, Rougier P, et al. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii41-8.
DOI: https://doi.org/10.1093/annonc/mds225
Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638-44.
DOI: https://doi.org/10.1136/gut.2009.187286
Leoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010;105:599-609.
DOI: https://doi.org/10.1038/ajg.2009.654
Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
DOI: https://doi.org/10.1002/bjs.1800600817
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
DOI: https://doi.org/10.1053/jhep.2001.22172
Lai JC, Feng S, Terrault NA, et al. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014;14:1870-9.
DOI: https://doi.org/10.1111/ajt.12762
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
DOI: https://doi.org/10.1097/00000421-198212000-00014
Karnofsky DA. The clinical evaluation of chemotherapeutic agents in cancer. New York, NY, USA: Columbia University Press; 1949.
Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993;67:773-5.
DOI: https://doi.org/10.1038/bjc.1993.140
Lai JC, Covinsky KE, Dodge JL, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017;66:564-74.
DOI: https://doi.org/10.1002/hep.29219
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022;76:681-93.
DOI: https://doi.org/10.1016/j.jhep.2021.11.018
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
DOI: https://doi.org/10.1016/S0140-6736(11)61347-0
de Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol 2012;56:S75-87.
DOI: https://doi.org/10.1016/S0168-8278(12)60009-9
Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant 2015;15:1-28.
DOI: https://doi.org/10.1111/ajt.13197
Yeh H, Smoot E, Schoenfeld DA, Markmann JF. Geographic inequity in access to livers for transplantation. Transplantation 2011;91:479-86.
DOI: https://doi.org/10.1097/TP.0b013e3182066275
Johnson RJ, Bradbury LL, Martin K, et al. Organ donation and transplantation in the UK-the last decade: a report from the UK national transplant registry. Transplantation 2014;97:S1-27.
DOI: https://doi.org/10.1097/01.TP.0000438215.16737.68
Freeman RB Jr., Steffick DE, Guidinger MK, et al. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008;8:958-76.
DOI: https://doi.org/10.1111/j.1600-6143.2008.02174.x
Northup PG, Intagliata NM, Shah NL, et al. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. Hepatology 2015;61:285-91.
DOI: https://doi.org/10.1002/hep.27283
Lai JC, Shui AM, Duarte-Rojo A, et al. Frailty, mortality, and health care utilization after liver transplantation: from the multicenter functional assessment in liver transplantation (FrAILT) study. Hepatology 2022;75:1471-9.
DOI: https://doi.org/10.1002/hep.32268
Dolnikov S, Adam R, Cherqui D, Allard MA. Liver transplantation in elderly patients: what do we know at the beginning of 2020? Surg Today 2020;50:533-9.
DOI: https://doi.org/10.1007/s00595-020-01996-7
Aloia TA, Knight R, Gaber AO, et al. Analysis of liver transplant outcomes for United Network for Organ Sharing recipients 60 years old or older identifies multiple model for end-stage liver disease-independent prognostic factors. Liver Transpl 2010;16:950-9.
DOI: https://doi.org/10.1002/lt.22098
Mittler J, Heinrich S, Koch M, et al. Elderly patients with hepatocellular carcinoma benefit from liver transplantation as much as younger ones. Liver Cancer 2023;12:171-7.
DOI: https://doi.org/10.1159/000528830
Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009;137:850-5.
DOI: https://doi.org/10.1053/j.gastro.2009.06.003
Pawlik TM, Esnaola NF, Vauthey JN. Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. Liver Transpl 2004;10:S74-80.
DOI: https://doi.org/10.1002/lt.20052
Cucchetti A, Sposito C, Pinna AD, et al. Effect of age on survival in patients undergoing resection of hepatocellular carcinoma. Br J Surg 2016;103:e93-9.
DOI: https://doi.org/10.1002/bjs.10056
Famularo S, Di Sandro S, Giani A, et al. The impact of age and ageing on hepatocarcinoma surgery: Short- and long-term outcomes in a multicentre propensity-matched cohort. Liver Int 2019;39:894-904.
DOI: https://doi.org/10.1111/liv.14075
Osei-Bordom D, Hall L, Hodson J, et al. Impact of frailty on short-term outcomes after laparoscopic and open hepatectomy. World J Surg 2022;46:2444-53.
DOI: https://doi.org/10.1007/s00268-022-06648-0
Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107:569-77.
DOI: https://doi.org/10.1038/ajg.2011.425
Takahashi H, Mizuta T, Kawazoe S, et al. Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients. Hepatol Research 2010;40:997-1005.
DOI: https://doi.org/10.1111/j.1872-034X.2010.00713.x
Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
DOI: https://doi.org/10.1016/S0140-6736(02)08649-X
Cohen MJ, Levy I, Barak O, et al. Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. Liver Int 2014;34:1109-17.
DOI: https://doi.org/10.1111/liv.12486
Nishikawa H, Kita R, Kimura T, et al. Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: clinical outcome and safety in elderly patients. J Cancer 2014;5:590-7.
DOI: https://doi.org/10.7150/jca.9413
Rabei R, Vakil P, King B, et al. Frailty as a predictor of complications and transplant-free survival after transarterial chemoembolization of hepatocellular carcinoma. J Clin Interv Radiol ISVIR 2022;07:027-033.
DOI: https://doi.org/10.1055/s-0042-1745775
Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 2021;74:2342-52.
DOI: https://doi.org/10.1002/hep.31819
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
DOI: https://doi.org/10.1002/hep.29913
Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 2019;49:1109-13.
DOI: https://doi.org/10.1111/hepr.13411
Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. J Natl Cancer Inst 2016;108:djw133.
DOI: https://doi.org/10.1093/jnci/djw133
Fernandez-Camacho E, Ferrer-Ramos C, Morilllo-Macias V, et al. The impact of frailty screening on radiation treatment modification. Cancers 2022;14:1072.
DOI: https://doi.org/10.3390/cancers14041072
Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy. Cancer J 2018;24:193-204.
DOI: https://doi.org/10.1097/PPO.0000000000000327
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.
DOI: https://doi.org/10.1056/NEJMoa1915745
Ozluk AA, Williams GR, Dai C, et al. Association between frailty and overall survival among older adults with hepatocellular carcinoma. J Geriatr Oncol 2024;15:102045.
DOI: https://doi.org/10.1016/j.jgo.2024.102045
Dauch J, Hamidi M, Arrington AK, et al. The impact of frailty on patients undergoing liver resection for colorectal liver metastasis. J Gastrointest Surg 2022;26:608-14.
DOI: https://doi.org/10.1007/s11605-021-05149-0
Hosoda K, Shimizu A, Kubota K, et al. Usefulness of frailty to predict short- and long-term outcomes in patients who have undergone major hepatectomy for perihilar cholangiocarcinoma. Ann Gastroenterol Surg 2022;6:833-41.
DOI: https://doi.org/10.1002/ags3.12596
Yamada S, Shimada M, Morine Y, et al. Significance of frailty in prognosis after hepatectomy for elderly patients with hepatocellular carcinoma. Ann Surg Oncol 2021;28:439-46.
DOI: https://doi.org/10.1245/s10434-020-08742-w
Almugbel FA, Timilshina N, AlQurini N, et al. Role of the vulnerable elders survey-13 screening tool in predicting treatment plan modification for older adults with cancer. J Geriatr Oncol 2021;12:786-92.
DOI: https://doi.org/10.1016/j.jgo.2020.12.002
Sugi T, Enomoto T, Ohara Y, et al. Risk factors for postoperative delirium in elderly patients undergoing gastroenterological surgery: a single-center retrospective study. Ann Gastroenterol Surg 2023;7:832-40.
DOI: https://doi.org/10.1002/ags3.12676
Sakano Y, Noda T, Kobayashi S, et al. Geriatric prognostic scoring system predicts survival after hepatectomy for elderly patients with liver cancer. Ann Gastroenterol Surg 2024;8:498-506.
DOI: https://doi.org/10.1002/ags3.12762
Tanaka S, Ueno M, Iida H, et al. Preoperative assessment of frailty predicts age-related events after hepatic resection: a prospective multicenter study. J Hepatobiliary Pancreat Sci 2018;25:377-87.
DOI: https://doi.org/10.1002/jhbp.568
Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993;342:1032-6.
DOI: https://doi.org/10.1016/0140-6736(93)92884-V
Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291:2441-7.
DOI: https://doi.org/10.1001/jama.291.20.2441
Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-10.
DOI: https://doi.org/10.7326/0003-4819-120-2-199401150-00002
Institute of Medicine Food Forum. Providing healthy and safe foods as we age: workshop summary. Washington, DC, USA: National Academies Press; 2010.
Khalil M, Di Ciaula A, Jaber N, et al. Multidimensional assessment of sarcopenia and sarcopenic obesity in geriatric patients: creatinine/cystatin c ratio performs better than sarcopenia index. Metabolites 2024;14:306.
DOI: https://doi.org/10.3390/metabo14060306
JafariNasabian P, Inglis JE, Kelly OJ, Ilich JZ. Osteosarcopenic obesity in women: impact, prevalence, and management challenges. Int J Womens Health 2017;9:33-42.
DOI: https://doi.org/10.2147/IJWH.S106107
Falsarella GR, Gasparotto LP, Barcelos CC, et al. Body composition as a frailty marker for the elderly community. Clin Interv Aging 2015;10:1661-6.
DOI: https://doi.org/10.2147/CIA.S84632
Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-31.
DOI: https://doi.org/10.1200/JCO.2007.10.6559
Moser A, Stuck AE, Silliman RA, et al. The eight-item modified Medical Outcomes Study Social Support Survey: psychometric evaluation showed excellent performance. J Clin Epidemiol 2012;65:1107-16.
DOI: https://doi.org/10.1016/j.jclinepi.2012.04.007
Clough-Gorr KM, Ganz PA, Silliman RA. Older breast cancer survivors: factors associated with change in emotional well-being. J Clin Oncol 2007;25:1334-40.
DOI: https://doi.org/10.1200/JCO.2006.09.8665
Ganz PA, Guadagnoli E, Landrum MB, et al. Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol 2003;21:4027-33.
DOI: https://doi.org/10.1200/JCO.2003.08.097
Horiuchi K, Kuno T, Takagi H, et al. Predictive value of the G8 screening tool for postoperative complications in older adults undergoing cancer surgery: a systematic review and meta-analysis. J Geriatr Oncol 2024;15:101656.
DOI: https://doi.org/10.1016/j.jgo.2023.101656
Loi M, Comito T, Franzese C, et al. Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy. J Geriatr Oncol 2021;12:1100-3.
DOI: https://doi.org/10.1016/j.jgo.2021.01.001
Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012;23:2166-72.
DOI: https://doi.org/10.1093/annonc/mdr587
Oldervoll LM, Loge JH, Lydersen S, et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist. 2011;16:1649-57.
DOI: https://doi.org/10.1634/theoncologist.2011-0133
Tsuchihashi J, Koya S, Hirota K, et al. Effects of in-hospital exercise on frailty in patients with hepatocellular carcinoma. Cancers 2021;13:194.
DOI: https://doi.org/10.3390/cancers13020194
Maharshi S, Sharma BC, Sachdeva S, et al. Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial. Clin Gastroenterol Hepatol 2016;14:454-60.e3.
DOI: https://doi.org/10.1016/j.cgh.2015.09.028
Lai JC, Shui AM, Duarte-Rojo A, et al. Association of frailty with health-related quality of life in liver transplant recipients. JAMA Surg 2023;158:130-8.
DOI: https://doi.org/10.1001/jamasurg.2022.6387
Rabei R, Fidelman N. Navigating hepatocellular carcinoma treatment in the context of frailty. Med Res Arch 2023;11:4493.
DOI: https://doi.org/10.18103/mra.v11i10.4493
How to Cite
Messina, G., & Palmieri, V. O. (2025). Hepatocellular carcinoma management in older adults and its relation with frailty. Geriatric Care, 11(1). https://doi.org/10.4081/gc.2025.13157
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.